These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 272984)

  • 1. Glucose-containing oligosaccharides in the urine of patients with glycogen storage disease type II and type III.
    Lennartson G; Lundblad A; Lundsten J; Svensson S; Häger A
    Eur J Biochem; 1978 Feb; 83(2):325-34. PubMed ID: 272984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased urinary excretion of a glycogen-derived tetrasaccharide in heterozygotes with glycogen storage diseases type II and III.
    Chester MA; Lundblad A; Häger A; Sjöblad S; Loonen C; Tager JM; Zopf D
    Lancet; 1983 Apr; 1(8331):994-5. PubMed ID: 6132305
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases.
    Sluiter W; van den Bosch JC; Goudriaan DA; van Gelder CM; de Vries JM; Huijmans JG; Reuser AJ; van der Ploeg AT; Ruijter GJ
    Clin Chem; 2012 Jul; 58(7):1139-47. PubMed ID: 22623745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic glycogenosis with defects in the glycogen breakdown pathway: urinary oligosaccharide profile.
    Giros ML; Alvarez L
    J Inherit Metab Dis; 1991; 14(3):311-3. PubMed ID: 1770780
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe's disease).
    Hallgren P; Hansson G; Henriksson KG; Häger A; Lundblad A; Svensson S
    Eur J Clin Invest; 1974 Dec; 4(6):429-33. PubMed ID: 4531383
    [No Abstract]   [Full Text] [Related]  

  • 6. Abnormal urinary oligosaccharide pattern in patients with glycogen storage disease, type III.
    McLaren J; Ng WG; Roe T
    Clin Chem; 1980 Dec; 26(13):1924-5. PubMed ID: 6934040
    [No Abstract]   [Full Text] [Related]  

  • 7. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases.
    Manwaring V; Prunty H; Bainbridge K; Burke D; Finnegan N; Franses R; Lam A; Vellodi A; Heales S
    J Inherit Metab Dis; 2012 Mar; 35(2):311-6. PubMed ID: 21687968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutral oligosaccharides in the urine of a patient with glycogen storage disease type II.
    Kuriyama M; Hiwatari R; Ariga T; Sakano Y; Abe J; Osame M; Igata A
    J Biochem; 1985 Oct; 98(4):1041-7. PubMed ID: 3935646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry.
    Lennartson G; Lundblad A; Sjöblad S; Svensson S; Ockerman PA
    Biomed Mass Spectrom; 1976 Apr; 3(2):51-4. PubMed ID: 817751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and immunochemical analysis of three alpha-limit dextrin oligosaccharides.
    Kumlien J; Grönberg G; Nilsson B; Månsson O; Zopf D; Lundblad A
    Arch Biochem Biophys; 1989 Mar; 269(2):678-89. PubMed ID: 2919890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal oligosaccharide pattern in glycogen storage disease type III.
    Galvin-Parton P; Hommes FA
    J Inherit Metab Dis; 1996; 19(3):383-4. PubMed ID: 8803792
    [No Abstract]   [Full Text] [Related]  

  • 12. Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry.
    Rozaklis T; Ramsay SL; Whitfield PD; Ranieri E; Hopwood JJ; Meikle PJ
    Clin Chem; 2002 Jan; 48(1):131-9. PubMed ID: 11751548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry.
    Young SP; Stevens RD; An Y; Chen YT; Millington DS
    Anal Biochem; 2003 May; 316(2):175-80. PubMed ID: 12711338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases.
    Oberholzer K; Sewell AC
    Clin Chem; 1990 Jul; 36(7):1381. PubMed ID: 2372959
    [No Abstract]   [Full Text] [Related]  

  • 15. [Acid hydrolysis of urinary oligosaccharides in type I glycogenosis].
    Sánchez-Corona J; Mora-García HA; Contreras-Sánchez O
    Arch Invest Med (Mex); 1990; 21(4):349-51. PubMed ID: 1669224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The decision-making levels of urine tetrasaccharide for the diagnosis of Pompe disease in the Turkish population.
    Canbay E; Vural M; Kalkan Uçar S; Sezer ED; Karasoy H; Yüceyar AN; Çoker M; Sözmen EY
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):391-395. PubMed ID: 32069240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases.
    Heiner-Fokkema MR; van der Krogt J; de Boer F; Fokkert-Wilts MJ; Maatman RGHJ; Hoogeveen IJ; Derks TGJ
    Genet Med; 2020 Nov; 22(11):1915-1916. PubMed ID: 32655139
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX.
    Cabrera-Abreu J; Crabtree NJ; Elias E; Fraser W; Cramb R; Alger S
    J Inherit Metab Dis; 2004; 27(1):1-9. PubMed ID: 14970741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemical specificity of the combining site of murine myeloma protein CAL20 TEPC1035 reactive with dextrans.
    Sugii S; Kabat EA; Shapiro M; Potter M
    J Exp Med; 1981 Jan; 153(1):166-81. PubMed ID: 6161205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glycogen storage disease].
    Kono N; Tarui S
    Nihon Rinsho; 1990 Jul; 48(7):1504-9. PubMed ID: 2402067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.